Verrica Pharmaceuticals (STU:1NE0) Cash Flow for Dividends: €0.00 Mil (TTM As of Mar. 2026)


STU:1NE0 Verrica Pharmaceuticals Inc STU:1NE0
45 GF Score
Price €5.31
GF Value €12.59
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Verrica Pharmaceuticals Cash Flow for Dividends?

Verrica Pharmaceuticals STU:1NE0 -0.56% 45 Cash Flow for Dividends is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:1NE0 with a GF Score™ of 45/100 and a GF Value™ of €12.59 (Possible Value Trap). The stock has 2 warning signs investors should review.

Verrica Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2026 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Verrica Pharmaceuticals Cash Flow for Dividends Related Terms

Verrica Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Verrica Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verrica Pharmaceuticals Cash Flow for Dividends Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Verrica Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:1NE0
45GF Score
Verrica Pharmaceuticals Inc STU:1NE0
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Verrica Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
Verrica Pharmaceuticals (STU:1NE0) has a Cash Flow for Dividends of €0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Verrica Pharmaceuticals and its competitors.
Is Verrica Pharmaceuticals' Cash Flow for Dividends too high?
Verrica Pharmaceuticals' current Cash Flow for Dividends is €0.00 Mil. Overall, Verrica Pharmaceuticals has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Cash Flow for Dividends compare to ENGN and PEPG?
Verrica Pharmaceuticals' Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Verrica Pharmaceuticals and its competitors. Verrica Pharmaceuticals's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (STU:1NE0) is currently considered Possible Value Trap. The stock's GF Value™ is €12.59, compared to a current price of €5.31 — trading 57.8% below its estimated fair value. The current Cash Flow for Dividends is €0.00 Mil. Verrica Pharmaceuticals' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Verrica Pharmaceuticals (STU:1NE0), the current Cash Flow for Dividends is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of €5.31 is trading 57.8% below its estimated GF Value™ of €12.59. GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:1NE0:

  • Cash Flow for Dividends: €0.00 Mil
  • GF Value™: €12.59 vs. price of €5.31 (57.8% below fair value)
  • GF Score™: 45/100 with 2 warning signs

No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Verrica Pharmaceuticals Business Description

Other Exchanges VRCA:USA1NE0:Germany
Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
45GF Score

Get the complete analysis for STU:1NE0

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.31
Price
€12.59
GF Value